Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...
AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...
Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce ...
Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...
Paige Mahaney, Ph.D. Chief Scientific Officer Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience ...
Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...
Knowledge on the genetic basis of Parkinson's disease has grown tremendously since the discovery of the first monogenic form, ...
NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will be presenting its ...
MANILA, Philippines — The government has added 23 projects to its public-private partnership (PPP) pipeline, expanding the total to 173 projects worth P3.17 trillion. The additional projects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback